All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Steven Le Gouill, CHU de Nantes, Nantes, FR, discusses sequencing of therapy for patients with TP53-mutated mantle cell lymphoma (MCL).
Welcome to the Lymphoma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following questions to help us gauge your current understanding of the sequencing of therapy for patients with TP53-mutated MCL.
Le Gouill begins by presenting a patient case and discussing the significance of prognostic markers, especially for relapsed cases. The presentation outlines prognostic data around relevant MCL patient characteristics, including the MANTLE-FIRST trial. Le Gouill goes on to review currently available treatment options, as well as introducing novel agents in MCL. Finally, he discusses the encouraging results of the AIM and OAsIs trials, which combine ibrutinib and venetoclax, and ibrutinib, venetoclax, and obinutuzumab, respectively.
Satellite Symposium | Sequencing of therapy for a patient with TP53-mutated MCL
If you would like to download the slides from Steven Le Gouill's presentation, click below.Download here
What was new in MCL at ASCO and EHA 2020?
Interview with Simon Rule, Derriford Hospital. We asked, What was new in mantle cell lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual...
Results from the OAsis phase I/II trial on ibrutinib, venetoclax plus obinutuzumab in patients with newly diagnosed mantle cell lymphoma
During the 2020 European Hematology Association (EHA) Annual Congress, Steven Le Gouill presented data from...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox